Mar. 30 at 2:46 PM
Insmed shares rose Monday as analysts reacted to positive data from United Therapeutics and a rating upgrade from Morgan Stanley to Overweight. The firm raised its price target to
$212 following a March 2026 AlphaWise survey of 75 U.S. pulmonologists, showing strong early adoption of Brinsupri, with 85% having prescribed it, current patient share around 12%, and expectations of reaching 21% by year-end.
United Therapeutics also reported positive Phase 3 TETON-1 data for Tyvaso in idiopathic pulmonary fibrosis , with placebo-adjusted FVC improvement of ~130 ml, above TETON-2 (~96 ml). Analysts said this supports the inhaled prostacyclin class ahead of Insmed’s planned Phase 3 trials for TPIP in IPF and progressive pulmonary fibrosis in 2H26.
Jefferies , Leerink (Outperform,
$215 PT), and Stifel all reaffirmed bullish views, citing strong Brinsupri momentum and significant long-term potential for TPIP, with peak sales estimates approaching
$5 billion across indications.
$INSM $UTHR